Boundless Bio Inc

Boundless Bio maintains a strong liquidity position with a current ratio of 20.45, indicating that its current assets significantly exceed its current liabilities. The company's cash and equivalents amount to $31.36 million, which is a substantial portion of its total assets of $188.20 million. The absence of long-term debt further supports its liquidity profile, with a debt-to-equity ratio of 0.0. The company's profitability metrics are currently negative, with a return on equity (ROE) of -9.47% and a return on assets (ROA) of -9.02%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income and net income are both negative, at -$19.39 million and -$16.98 million, respectively. These results are below the typical performance metrics for the biotechnology industry, which often includes high R&D expenditures and long development cycles before revenue generation. Boundless Bio's revenue is not disclosed in the provided data, and there are no specific segments or geographic regions mentioned. However, the company's operations are likely concentrated in the United States, as is common for many biotechnology firms. The lack of detailed segment or geographic data limits the ability to assess revenue concentration risks. The company's growth trajectory is not clearly defined in the provided data, as there are no specific revenue growth figures or future projections. The operating cash flow is negative at -$32.01 million, and the free cash flow is also negative at -$18.18 million. These figures suggest that the company is currently investing heavily in its operations and may not be generating positive cash flows from its core business activities. The risk assessment for Boundless Bio indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's capital structure is relatively simple, with no long-term debt and a low number of shares outstanding. However, the negative net income and operating cash flow suggest that the company may need to raise additional capital in the future, which could lead to dilution for existing shareholders. The dilution potential is currently assessed as low, but this could change if the company's financial position deteriorates. Recent events and filings do not provide specific details on Boundless Bio's operations or financial performance. The company's IR observations show that analysts have a mean price target of $4.00, with a median and high price target also at $4.00. The mean recommendation is 3.00, indicating a "hold" rating, with no strong buy or buy recommendations. This suggests that analysts are cautious about the company's near-term prospects and are not recommending significant investment at this time.